Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANO-3 nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer
NL-OMON59063Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab in esophageal cancer and esophagogastric junction cancer, sponsored by Erasmus MC. Primary endpoint: Disease-free survival. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON59063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59063.